Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation Sir, Chronic myeloid leukaemia (CML) is a rare malignant complication in solid organ recipients [1] . Imatinib mesylate, a potent inhibitor of the Bcr-Abl protein tyrosine kinase encoded by the Philadelphia chromosome, has proven to be effective and is currently approved for first-line treatment of CML. The goal of imatinib treatment is to achieve not only cytogenetic remission, but also complete molecular remission, as defined by undetectable blood levels of BCR-ABL transcripts using quantitative polymerase chain reaction (PCR). Although cytogenetic remission of de novo CML with imatinib therapy has been recently reported in a renal transplant patient [2] , the efficiency and tolerance of the strategy in this particular population remains to be confirmed.
In July 2000, a 53-year-old Caribbean woman received a cadaveric kidney transplant for end-stage renal failure secondary to diabetic nephropathy. Immunosuppressive treatment consisted of anti-thymocyte globulin, ciclosporin A (CsA), mycophenolate mofetil (MMF) and steroids. In August 2002, she developed CML (leukocytosis 28.6 Â 10 9 /l, Table 1 ) confirmed by cytogenetic analysis of bone marrow smears. Imatinib was started at conventional dose of 400 mg daily, while CsA and MMF were maintained. Seven weeks later, imatinib was transiently discontinued because of neutropenia, and resumed at 300 mg daily with a 25% reduction in CsA dose. Worsening of glycaemic control required combined oral antidiabetic and insulin therapy. In April 2003, MMF was switched to azathioprine because of chronic diarrhoea. At this time, the patient had achieved complete cytogenetic and molecular response, with bcr-abl/abl ratio <0.01% by PCR, which was maintained at last follow-up (Table 1) . In January 2004, a breast cancer was diagnosed. A complete remission was obtained with mastectomy, radiotherapy and hormonal treatment. An allograft biopsy, performed because of progressive degradation of renal function (creatininaemia 203 mmol/l, without proteinuria), revealed border-line cellular rejection and grade I chronic allograft nephropathy without peritubular capillaries C4d deposits, but diffuse staining of glomerular and tubular basement membranes with anti-gamma, anti-kappa, anti-lambda and anti-albumin conjugates, as expected because of diabetes. Arterial and arteriolar sections appeared nearly normal without fibrous endarteritis, nor subendothelial hyalinosis (Figure 1 ).
In conclusion, we report the first case of sustained molecular remission of CML with first line prolonged imatinib therapy in a renal allograft recipient. With slight reduction of CsA and imatimib doses, both substrates of CYP3A4, tolerance of imatimib therapy was good. That our patient required intensification in antidiabetic therapy does not support recent data suggesting beneficial effects of imatinib on glycaemic and lipid control [3, 4] . Imatinib is also a selective PDGF-R tyrosine kinase inhibitor with vascular antiproliferative properties, including prevention of chronic allograft nephropathy [5] , or reduction of heart allograft arteriosclerosis [6] in animals. Although a beneficial role of imatimib in the prevention of chronic renal allograft vasculopathy remains unproven, imatimib was a safe therapy in our patient, with almost normal vascular sections despite grade I chronic allograft nephropathy on a late kidney biopsy. 
Case
An 81-year-old man with end-stage renal disease secondary to hypertensive nephrosclerosis has been on chronic haemodialysis since February 2006. He is dialysed for 4 h three times a week, with a synthetic polyarylethersulphone/ polyamide membrane (Polyflux 17L, Gambro). He also suffers from atherosclerotic cardiac and vascular disease, congestive heart failure (left ventricular ejection fraction of 40%) and atrial fibrillation. His medication includes aspirin, warfarin, metoprolol, lisinopril, furosemide, erythropoietin, intravenous iron, allopurinol and clonazepam. The patient was taking a combination of hydralazine and nitrate, which was replaced by a small dose of lisinopril (2.5 mg once daily) shortly after he began haemodialysis. The patient underwent ophthalmic surgery in May 2006. His usual dialyzer was replaced by a surface-treated AN69 membrane (Nephral ST 400, Gambro) for the next dialysis treatments. On 15 May 2006, the patient presented with a hypotensive episode. His blood pressure was 114/64 just before the start of haemodialysis, and dropped to 82/39 about 1h 30 min later. Boluses of normal saline were given, but the dialysis had to be stopped because of persisting hypotension. The patient finally quit the dialysis unit with a blood pressure of 111/75. On the next session, two days later, he once again experienced a blood pressure drop from 116/69 to 86/48 in the first hour of dialysis. This time, however, he also complained of severe abdominal cramps and had massive diarrhoea. The session was stopped immediately, with symptoms resolving spontaneously. The dialyzer was changed back to Polyflux 17L at the next dialysis, with no recurrence of hypotension or intestinal symptoms. At the time, we did not link the ST-AN69 membrane to the patient's manifestations.
On 23 and 25 October 2006, a Nephral ST 400 (from a different lot) was reintroduced because of a temporary contraindication to anticoagulation (fistulography with angioplasty). Less than 1 h after the beginning of the dialysis, abdominal pain and diarrhoea recurred. The patient had no hypotension this time. The surface-treated AN69 membrane was suspected to be responsible and the next haemodialysis was started with the patient's former dialyzer, with no other adverse event. Lisinopril was continued.
The AN69 membrane has one of the highest electronegativity of all dialysis membranes, due to the methylsulphonate radicals. This electronegativity is known to enhance bradykinin production [5, 6] . By preventing degradation of bradykinin, ACEI can raise bradykinin to potentially harmful levels (as much as 20-30-fold). Polyethyleneimine (PEI) is a polycationic saline solution used to coat the surface Fig. 1 . Renal graft biopsy, light microscopy, silver staining, original magnification 400Â. Proximal interlobular artery with normal intima and media, surrounded by lymphocytes and few plasma cells.
